Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Systemic lupus erythematosus and lupus nephritis

Nature Reviews Drug Discovery volume 13, pages 173–174 (2014)Cite this article

Subjects

The clinical course of SLE can vary from mild symptoms to life-threatening multi-organ disease. We estimate that there were approximately 0.45 million diagnosed cases of SLE in 2012 in the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan), a number that is expected to grow steadily to 0.48 million by 2022 owing to increases in the population and life expectancy, and improvements in disease awareness and diagnosis1.

Current therapies

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Drug sales for SLE in the seven major markets in terms of market value and volume in 2012 and 2022 (estimated).

References

  1. Koutsokeras, T. & Healy, T. PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis — Global Drug Forecast and Market Analysis to 2022 (GlobalData, 2013).

    Google Scholar 

  2. Lateef, A. & Petri, M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res. Ther. 14, S4 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GlobalData, 40–42 Hatton Garden, London, EC1N 8EB, UK

    Toli Koutsokeras

  2. GlobalData, 40–42 Hatton Garden, London, EC1N 8EB, UK

    Tina Healy

Authors
  1. Toli Koutsokeras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tina Healy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Toli Koutsokeras or Tina Healy.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koutsokeras, T., Healy, T. Systemic lupus erythematosus and lupus nephritis. Nat Rev Drug Discov 13, 173–174 (2014). https://doi.org/10.1038/nrd4227

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4227

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing